Mission to deplete

Mission Therapeutics Ltd. believes it can produce a first-in-class compound against the deubiquitinating enzyme UCHL1 ready to begin Phase I trials by the end of next year.

The strategy of depleting ubiquitin carboxyl-terminal esterase L1 (UCHL1) and other enzymes in the class allows the company to attack the ubiquitin-proteasome pathway upstream of the target of proteasome inhibitors such as Velcade bortezomib and Kyprolis carfilzomib...